AI assistants crack drug-retargeting tasks

AI assistants crack drug‑retargeting

Two AI‑based science assistants have demonstrated success on drug‑retargeting tasks. The tools generate hypotheses and, in one case, push the workflow further by analyzing some of the data. The result is a streamlined pipeline that moves from idea to preliminary validation without human‑crafted assays.

The experiment shows that hypothesis generation is no longer a purely manual step. By letting an algorithm propose candidate compounds, researchers can screen larger chemical spaces. The follow‑up analysis performed by one of the assistants adds a layer of quantitative assessment that would otherwise require a separate software stack.

The outcome does not claim a breakthrough in clinical efficacy, but it does prove that AI can handle end‑to‑end components of early‑stage drug discovery. The finding aligns with a broader push to automate repetitive research tasks.

NASA chief pushes for cheap satellite constellations

“I’ll buy 10 of those,” the NASA science chief said, expressing a desire for mass‑produced satellites. The comment followed a statement: “How in the hell do I get more science into space? That is my goal.” The chief’s remarks underline a frustration with the high cost and long lead times of traditional spacecraft.

Mass production promises to lower per‑unit cost and accelerate deployment. If NASA can procure dozens of identical platforms, it could field experiments that were previously too expensive or risky. The approach also opens the door to rapid iteration on sensor designs.

Critics warn that a flood of cheap satellites could increase orbital debris. The chief’s push therefore sits at the intersection of scientific ambition and sustainability concerns.

Musk‑Altman feud surfaces governance questions

Elon Musk recently accused Sam Altman of “stealing” a non‑profit, a claim that resurfaced during a trial. Musk added, “By the end of this week, you and Sam will be the most hated men in America.” The statement reflects a personal and public clash between two leading AI figures.

The dispute centers on the direction of AI development and the control of powerful models. Musk’s allegation suggests a perceived appropriation of resources, while Altman’s side argues for open‑access principles. The trial highlighted that both executives share similar aims despite their public antagonism.

The feud is more than a headline; it signals a broader governance dilemma. As AI systems become capable of scientific discovery, the question of who steers their use grows urgent.

Context: convergence of AI, space and cultural narratives

The final trailer for Spider‑Noir, released this week, positions the antagonist as a classic villain. While a entertainment product, the trailer reflects a cultural appetite for clear‑cut adversaries in an era where technology blurs ethical lines.

When AI tools enter drug discovery and satellite manufacturing scales up, the stakes resemble a narrative conflict. On one side, accelerated science promises breakthroughs; on the other, governance disputes and environmental risks act as antagonists.

Historically, rapid tech adoption has outpaced policy. The current mix of AI‑driven research, cheap satellite ambitions, and high‑profile leadership clashes suggests a repeat of past cycles where regulation lags behind capability.

What to watch

Track NASA’s procurement announcements for a batch order of standardized satellites within the next six months. Monitor the outcomes of the ongoing legal proceedings involving Musk and Altman, as any rulings could shape AI governance frameworks. Finally, watch for follow‑up studies from the two AI science assistants to see whether their drug‑retargeting results translate into pre‑clinical validation.

Updates

• 2026-05-29 — Apple spotlights Detroit app makers as local Developer Academy marks fifth graduating class (source)
• 2026-05-22 — Tesla recalls thousands of Model Ys at risk of… missing a sticker (source)